250 related articles for article (PubMed ID: 18007201)
1. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.
Traficante A; Riozzi B; Cannella M; Rampello L; Squitieri F; Battaglia G
Neuroreport; 2007 Dec; 18(18):1997-2000. PubMed ID: 18007201
[TBL] [Abstract][Full Text] [Related]
2. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
3. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
[TBL] [Abstract][Full Text] [Related]
4. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
Gianfriddo M; Melani A; Turchi D; Giovannini MG; Pedata F
Neurobiol Dis; 2004 Oct; 17(1):77-88. PubMed ID: 15350968
[TBL] [Abstract][Full Text] [Related]
5. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.
Estrada-Sánchez AM; Montiel T; Segovia J; Massieu L
Neurobiol Dis; 2009 Apr; 34(1):78-86. PubMed ID: 19168136
[TBL] [Abstract][Full Text] [Related]
6. Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Rite I; Machado A; Cano J; Venero JL
Exp Neurol; 2005 Mar; 192(1):142-55. PubMed ID: 15698628
[TBL] [Abstract][Full Text] [Related]
7. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
[TBL] [Abstract][Full Text] [Related]
8. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment.
Rebec GV; Conroy SK; Barton SJ
Neuroscience; 2006; 137(1):327-36. PubMed ID: 16257492
[TBL] [Abstract][Full Text] [Related]
9. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF.
Cepeda C; Starling AJ; Wu N; Nguyen OK; Uzgil B; Soda T; André VM; Ariano MA; Levine MS
J Neurosci Res; 2004 Dec; 78(6):855-67. PubMed ID: 15505789
[TBL] [Abstract][Full Text] [Related]
10. Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions.
De March Z; Zuccato C; Giampà C; Patassini S; Bari M; Gasperi V; De Ceballos ML; Bernardi G; Maccarrone M; Cattaneo E; Fusco FR
Neuroscience; 2008 Mar; 152(3):734-40. PubMed ID: 18313855
[TBL] [Abstract][Full Text] [Related]
11. Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression.
Szapacs ME; Mathews TA; Tessarollo L; Ernest Lyons W; Mamounas LA; Andrews AM
J Neurosci Methods; 2004 Dec; 140(1-2):81-92. PubMed ID: 15589338
[TBL] [Abstract][Full Text] [Related]
12. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.
Freeman W; Morton AJ
Brain Res Bull; 2004 Mar; 63(1):45-55. PubMed ID: 15121238
[TBL] [Abstract][Full Text] [Related]
13. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse.
Chassain C; Bielicki G; Durand E; Lolignier S; Essafi F; Traoré A; Durif F
J Neurochem; 2008 May; 105(3):874-82. PubMed ID: 18088356
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
[TBL] [Abstract][Full Text] [Related]
15. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease.
Desplats PA; Kass KE; Gilmartin T; Stanwood GD; Woodward EL; Head SR; Sutcliffe JG; Thomas EA
J Neurochem; 2006 Feb; 96(3):743-57. PubMed ID: 16405510
[TBL] [Abstract][Full Text] [Related]
16. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
17. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
Crocker SF; Costain WJ; Robertson HA
Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
[TBL] [Abstract][Full Text] [Related]
18. Adenosine A 2A receptor deficiency reduces striatal glutamate outflow and attenuates brain injury induced by transient focal cerebral ischemia in mice.
Gui L; Duan W; Tian H; Li C; Zhu J; Chen JF; Zheng J
Brain Res; 2009 Nov; 1297():185-93. PubMed ID: 19703429
[TBL] [Abstract][Full Text] [Related]
19. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
[TBL] [Abstract][Full Text] [Related]
20. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.
Ferrante A; Martire A; Armida M; Chiodi V; Pézzola A; Potenza RL; Domenici MR; Popoli P
Brain Res; 2010 Apr; 1323():184-91. PubMed ID: 20138162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
